What is mild diffuse bronchiectasis and how should it be treated in a 62-year-old woman?

What is Mild Diffuse Bronchiectasis?

Mild diffuse bronchiectasis is a chronic respiratory condition characterized by permanent, irreversible dilation of the bronchi (airways) distributed throughout both lungs, rather than being confined to one area 1. The airways become damaged and widened, with thickened walls and impaired mucus clearance, leading to chronic cough, daily sputum production, and recurrent respiratory infections 2, 1. In mild cases, symptoms may be less severe but still impact quality of life.

Treatment Approach for a 62-Year-Old Woman

For a 62-year-old woman with mild diffuse bronchiectasis, treatment should begin with non-pharmacological airway clearance techniques and regular exercise, with pharmacological therapy added based on exacerbation frequency and specific bacterial colonization patterns 2.

Initial Management Framework

Non-Pharmacological Interventions (Strongly Recommended)

• Airway clearance techniques: These are strongly recommended for most bronchiectasis patients and form the cornerstone of therapy 2. Techniques include active cycle of breathing, autogenic drainage, or oscillating positive expiratory pressure devices to help mobilize and clear mucus.

• Pulmonary rehabilitation: Strongly recommended if the patient experiences dyspnea or impaired exercise capacity 2. This includes supervised exercise training and education to improve functional capacity and quality of life.

• Regular physical exercise: Even without formal rehabilitation, maintaining regular physical activity helps with mucus clearance and overall respiratory health 1, 3.

• Nebulized saline: Consider hypertonic saline nebulization to loosen tenacious secretions and facilitate airway clearance 1.

Pharmacological Treatment Algorithm

The decision to add medications depends primarily on exacerbation frequency and sputum microbiology results:

For Patients with <3 Exacerbations Per Year (Mild Disease)

• No routine long-term antibiotics needed 4
• Treat acute exacerbations promptly with 14-day courses of oral antibiotics based on sputum culture results 4
• Consider bronchodilators (β-agonists and/or antimuscarinic agents) only if concurrent asthma or COPD is present 1
• Do NOT routinely use inhaled corticosteroids unless asthma or COPD coexists 1

For Patients with ≥3 Exacerbations Per Year

Long-term antibiotic therapy is recommended 2, 4:

If Pseudomonas aeruginosa is chronically present:

• First-line: Inhaled colistin 1 MU twice daily (delivered through I-neb device) 4
• Second-line: Inhaled gentamicin if colistin is not tolerated 4
• Alternative or additive: Azithromycin 250-500 mg three times weekly (strongly recommended by 2025 ERS guideline) 2

Safety monitoring before starting inhaled aminoglycosides:

• Avoid if creatinine clearance <30 mL/min
• Use caution with significant hearing loss
• Monitor renal function and audiology 4

If NO Pseudomonas aeruginosa:

• Azithromycin or erythromycin as first-line long-term therapy 4
• Check baseline ECG (QTc interval) and liver function before starting macrolides
• Screen for nontuberculous mycobacteria (NTM) before initiating macrolides to avoid resistance 4

Critical Diagnostic Workup

Before initiating treatment, obtain:

1. Sputum cultures (spontaneous or induced) for bacteria, mycobacteria, and fungi 4, 1
2. Blood tests: Complete blood count, immunoglobulin levels (IgG, IgA, IgE, IgM) 1
3. Spirometry: Pre- and post-bronchodilator to assess airflow obstruction 1
4. CT chest: Already done for diagnosis, but review for extent and distribution 2

Management of Acute Exacerbations

Exacerbations present with increased cough, sputum volume/purulence, worsened fatigue, and sometimes systemic symptoms 4.

• Obtain sputum culture before starting antibiotics when possible 4

• Start empirical oral antibiotics for 14 days based on previous culture results 4:

  • Haemophilus influenzae: Amoxicillin 500 mg TID or amoxicillin-clavulanate 625 mg TID
  • Streptococcus pneumoniae: Amoxicillin 500 mg-1 g TID
  • Pseudomonas aeruginosa: Ciprofloxacin 500-750 mg BID
  • Moraxella catarrhalis: Amoxicillin-clavulanate 625 mg TID

• Provide antibiotics for home use so patients can start treatment promptly at exacerbation onset 4

Special Considerations for This Age Group

At 62 years old, this patient falls into a higher-risk age category (prevalence increases substantially with age) 1, 5:

• Screen for comorbidities: GERD (47% association), asthma (29%), COPD (20%) 1
• Assess for aspiration risk: Structural chest wall changes and impaired swallowing are more common in older adults 5
• Evaluate cognitive function and polypharmacy risks: Shared decision-making about treatment intensity should consider functional ability and medication burden 5
• Vaccination: Ensure up-to-date pneumococcal and annual influenza vaccines 2

When to Escalate Care

Refer to a bronchiectasis specialist if 2:

• Rapid clinical deterioration despite appropriate treatment
• Increasing exacerbation frequency or severity
• New isolation of Pseudomonas aeruginosa or NTM
• Declining lung function (FEV₁ dropping)
• Poor adherence to airway clearance techniques

Common pitfalls to avoid:

• Starting inhaled corticosteroids routinely without asthma/COPD—this is not recommended 1
• Failing to obtain sputum cultures before antibiotics, which limits targeted therapy
• Starting macrolides without screening for NTM, risking development of macrolide-resistant NTM 4
• Underutilizing airway clearance techniques, which are the foundation of therapy 2

Pseudomonas aeruginosa deserves special attention: It is the most frequently isolated pathogen and is independently associated with recurrent hospitalizations and higher mortality 6. If this is a new isolation, eradication therapy should be offered: ciprofloxacin 500-750 mg BID for 2 weeks, followed by 3 months of nebulized colistin, gentamicin, or tobramycin 4.